Multiple myeloma

New England Journal of Medicine

Volumn 336, Issue 23, 1997, Pages 1657-1665

  Bataille, Régis ^a,b   Harousseau, Jean Luc ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MELPHALAN; PHOSPHONIC ACID DERIVATIVE; RETINOIC ACID; VINCRISTINE;

BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; ERYTHROPOIETIN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-ALPHA; INTERLEUKIN-6; MULTIPLE MYELOMA;

EID: 0030908056     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199706053362307     Document Type: Review

References (100)

1. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992;6:225-47.
2. Kyle RA. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993;68:26-36.
3. Greipp PR, Kyle RA. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983;62:166-71.
4. Sukpanichnant S, Cousar JB, Leelasiri A, Graber SE, Greer JP, Collins RD. Diagnostic criteria and histologie grading in multiple myeloma: histologie and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol 1994;25:308-18.
5. Boccadoro M, Gavarotti P, Fossati G, et al. Low plasma cell 3(H) thymidinc incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy, Br J Haematol 1984; 58:689-96.
6. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995;86:3915-21.
7. Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 1996;87:4762-9.
8. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Hematol 1989;26:176-200.
9. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 1993;72:219-24.
10. Gold JE, Schwam L, Castella A, Pike SB, Opfell R, Zalusky R. Malignant plasma cell tumors in human immunodeficiency virus-infected patients. Cancer 1990;66:363-8.
11. Salmon SE, Seligmann M. B-cell neoplasia in man. Lancet 1974;2: 1230-3.
12. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
13. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinaemia and monoclonal gammopathies. In: Hoffbrand AV, Brain MC, Hirsh J, eds. Recent advances in haematology. No. 2. Edinburgh, Scotland; Churchill Livingstone, 1977:243-61.
14. Idem. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
15. Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance. Br J Haematol 1973;24:123-39.
16. Alexanian RA, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer 1975;36:1192-201.
17. Durie BGM, Salmon SE, Moon TE. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980;55:364-72.
18. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273-84.
19. Cogne M, Silvain C, Khamlichi AA, PrcucThomme JL, Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood 1992;79:2181-95.
20. Kyle RA, Beard CM, O'FaUon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota, 1978 through 1990, with a review of the trends since 1945. J Clin Oncol 1994;12:1577-83.
21. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993;94:57-61.
22. Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma, J Clin Oncol 1995;13:251-6.
23. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993;11:1311-5.
24. MacLennan ICM, Hardie DL, Ball J, Drew M. Antibody-secreting cells and their origins. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: biology and management. Oxford, England: Oxford University Press, 1995:30-49.
25. Graham RC Jr, Bernier GM.The bone marrow in multiple myeloma: correlation of plasma cell ultrastructure and clinical state. Medicine (Baltimore) 1975;54:225-43.
26. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658-63.
27. Salmon SE. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973;10:135-44.
28. Latreille J, Barlogic B, Dosik G, Johnston DA, Drewinko B, Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood 1980;55:403-8.
29. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985;66:380-90.
30. Fritz E, Ludwig H, Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. Blood 1984;63:1072-9.
31. Greipp PR, Raymond NM, Kyle RA, O'Fallon M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985;65:305-10.
32. Barlogie B, Alexanian R, Gehan EA, Smallwood L, Smith T, Drewinko B. Marrow cytometry and prognosis in myeloma, J Clin Invest 1983;72: 853-61.
33. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
34. Bakkus MHC, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992;80:2326-35.
35. Ralph QM, Brisco MJ, Joshua DE, Brown R, Gibson J, Morley AA. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood 1993;82:202-6.
36. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood 1981;57:333-8.
37. Greil R, Fasching B, Loidl P, Huber H. Expression of the c-myc protooncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood 1991;78:180-91.
38. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 1993;81:2708-13.
39. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo A. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993;81:128-35.
40. Pellat-Deceunynck C, Barille S, Puthier D, et al. Adhesion molecules on human plasma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995;55:3647-53.
41. Liu P, Leong T, Quam L, et aL Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996;88: 2699-706.
42. Witzig TE, Dhodapkar MV, Kyie RA, Greipp PR. Quantification of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993;72:108-13.
43. Kawano M, Hirano T, Matsuda T, et ah Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83-5.
44. Klein B, Zhang XG, Jourdan M, et al. Paracrine but not autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
45. Hardin J, MacLeod S, Grigorieva I, et aL Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994,84:3063-70.
46. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-204.
47. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumor necrosis factor-a in human multiple myeloma. Br J Haematol 1990;74:424-31.
48. Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-4.
49. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992;6:285-95.
50. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
51. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
52. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-9.
53. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-5.
54. Barlogie B, Alexanian R, Smallwood L, et al. Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 1988;72: 2015-9.
55. Cunningham D, Paz-Ares L, Gore ME, et al. High-dose melphalan for multiple myeloma; long-term follow-up data. J Clin Oncol 1994;12: 764-8.
56. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992;79:2827-33.
57. Barlogie B, Jagannath S, Dixon DO, et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990;76:677-80.
58. Harousseau JL, Facon T, Maloisel F, et al. G-CSF instead of autologous stem cell transplantation after high dose melphalan as front-line therapy in multiple myeloma. Blood 1995;86:Suppl 1:184a. abstract.
59. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous hone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
60. Attaf M, Harousseau JL. Autologous transplantation in multiple myeloma. In: Gahrton G, Duric BGM, eds. Multiple myeloma. London: Arnold, 1996:182-93.
61. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma; a report of the French Registry on Autologous Transplantation in Multiple Myeloma. Blood 1995;85:3077-85.
62. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79:1130-6.
63. Fermand JP, Chevret S, Ravaud P, et al. High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993;82:2005-9.
64. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
65. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-96.
66. Lemoli RM, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996;87: 1625-34.
67. Reece DE, Barnett MJ, Connors JM, et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993;11:139-46.
68. Anderson KC, Andersen J, Soiffer R, et al. Monoclonal antibodypurged bone marrow transplantation therapy for multiple myeloma. Blood 1993;82:2568-76.
69. Schiller G, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995;86:390-7
70. Gazitt Y, Reading CC, Huffman R, et al. Purified CD34+ LinThy+ stem cells do not contain clonal myeloma cells. Blood 1995;86:381-9.
71. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;84:950-6.
72. Vesole DH, Tricot G, Jagannath S, et al. Au to transplants in multiple myeloma: what have we learned? Blood 1996;88:838-47.
73. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple mycloma. J Clin Oncol 1995;13: 1312-22.
74. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8.
75. Harousseau JL. Therapeutic use of cytokines in human multiple myeloma. In: Klein B, ed. Cytokines in human multiple myeloma. Austin, Tex.: R.G. Landes, 1994:97-112.
76. Mandelli F, Avvisati G, Amadori S, et al. Maintenance therapy with recombinant Interferon alfa-2b in patients with multiple myeloma respond- ing to conventional induction chemotherapy. N Engl J Med 1990;322: 1430-4.
77. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2405-14.
78. Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomised study. Br J Haematol 1995;89:561-8.
79. Browman GP, Bergsagel DE, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995;13:2354-60.
80. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group, Eur J Cancer 1995;31A:146-51.
81. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha ha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995;6:467-76.
82. The Nordic Myeloma Study Group. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Intern Med 1996;124:212-22.
83. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + α-interferon. Br J Haematol 1996;94:324-32.
84. Cunningham D, Powles R, Malpas JS, et al. A randomised trial of maintenance therapy with intronA following high dose melphalan and ABMT in myeloma. J Clin Oncot 1993;12:364. abstract.
85. Osterborg A, Bjorkholm M, Bjoreman M, et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993;81:1428-34.
86. Cooper MR, Dear K, McIntyre OR, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993;11:155-60.
87. Corrado C, Pavlovsky S, Saslasky J, Lein J, Palau V, Santarelli MT. Randomized trial comparing melphalan-prednisone with or without recombinant alfa 2 interferon (r α 2 IFN) in multiple myeloma. J Clin Oncol 1989; 8:258. abstract.
88. Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A. Alpha-2-interferon/meJphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990;76:365-8.
89. α2) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase III trial. Blood 1995;86:Suppl l:441a. abstract.
90. Casassus P, Pegourie-Bandelier B, Sadoun A, et al. Randomized comparison of interferon-α with VMCP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multicentre trial. Blood 1995;86:Suppl 1:441a. abstract.
91. Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 1993;72:2589-92.
92. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991;9:1397-402.
93. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52. [Erratum, Lancet 1992;340:1420.]
94. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
95. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or nonHodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-53.
96. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemia patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-82.
97. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
98. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995;86:3043-9.
99. Massaia M, Borrione P, Attisano C, et al. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 1995;85:3679-87.
100. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotypespecific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.